source
- Final Medicare rule to curb doctor-administered drug prices covers only four firms, delivering far less savings than proposedThe Trump administration released a final rule intended to lower Medicare prices for drugs given in doctors' offices. The rule applies only to four pharmaceutical companies, a far narrower scope t…
- Kallyope rebrands as TriGemX Bio, secures $94M to fund Phase 3 migraine trialKallyope, a New York City drug developer, announced it is changing its name to TriGemX Bio as it narrows its pipeline to migraine. The rebrand follows a recent partnership with Novo on an obesity…